Teacher Retirement System of Texas Buys 14,801 Shares of AbbVie Inc. $ABBV

Teacher Retirement System of Texas grew its stake in shares of AbbVie Inc. (NYSE:ABBV) by 2.6% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 589,752 shares of the company’s stock after buying an additional 14,801 shares during the quarter. AbbVie makes up 0.5% of Teacher Retirement System of Texas’ holdings, making the stock its 29th biggest holding. Teacher Retirement System of Texas’ holdings in AbbVie were worth $134,752,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Vanguard Group Inc. grew its stake in shares of AbbVie by 0.3% during the third quarter. Vanguard Group Inc. now owns 177,747,261 shares of the company’s stock worth $41,155,601,000 after buying an additional 448,554 shares during the last quarter. Legal & General Group Plc lifted its holdings in shares of AbbVie by 4.3% during the third quarter. Legal & General Group Plc now owns 12,004,084 shares of the company’s stock worth $2,779,426,000 after purchasing an additional 493,420 shares during the period. Wellington Management Group LLP lifted its holdings in shares of AbbVie by 457.4% during the third quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock worth $2,439,714,000 after purchasing an additional 8,646,424 shares during the period. Amundi lifted its holdings in shares of AbbVie by 15.6% during the third quarter. Amundi now owns 10,508,317 shares of the company’s stock worth $2,418,909,000 after purchasing an additional 1,414,621 shares during the period. Finally, Ameriprise Financial Inc. lifted its holdings in shares of AbbVie by 4.4% during the third quarter. Ameriprise Financial Inc. now owns 9,675,877 shares of the company’s stock worth $2,241,363,000 after purchasing an additional 408,426 shares during the period. Institutional investors own 70.23% of the company’s stock.

AbbVie Stock Down 2.3%

ABBV stock opened at $200.43 on Thursday. AbbVie Inc. has a 12-month low of $174.40 and a 12-month high of $244.81. The firm has a market cap of $354.39 billion, a price-to-earnings ratio of 84.93, a PEG ratio of 0.73 and a beta of 0.38. The company’s fifty day simple moving average is $217.87 and its 200 day simple moving average is $222.77.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The firm had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. During the same period in the previous year, the firm posted $2.16 earnings per share. The business’s revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Research analysts expect that AbbVie Inc. will post 14.22 earnings per share for the current year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 3.5%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s payout ratio is 293.22%.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Canaccord initiated coverage with a Buy/strong-buy and a $262 price target (implies ~29% upside), signaling Wall Street confidence in AbbVie’s multi-franchise growth profile and boosting investor demand. Canaccord Calls AbbVie a Core Holding With a $262 Target
• Positive Sentiment: AbbVie announced a $1.4 billion, 185?acre manufacturing campus in Durham, NC — its largest single-site investment — expanding AI-enabled production capacity for immunology, neuroscience and oncology drugs and creating ~734 permanent jobs. This strengthens supply chain control and supports future volume growth. AbbVie to build $1.4 billion manufacturing campus in North Carolina
• Positive Sentiment: AbbVie struck an exclusive licensing deal with Haisco Pharmaceutical Group to develop, manufacture and commercialize novel pain medicines — a potential pipeline expansion and commercialization pathway that could add new revenue streams if assets advance. AbbVie Inc. (ABBV) Inks Licensing Agreement for Pain Medicines Development
• Positive Sentiment: Late-breaking Phase 2 data for AbbVie’s ADC mirvetuximab (ELAHERE) and the Durham AI plant narrative have been highlighted as factors that could reframe the bull case — suggesting improving oncology prospects alongside manufacturing-led efficiency gains. These developments underpin bullish commentary in several outlets. Does AbbVie’s Durham AI Plant and Ovarian Cancer Data Reframe the Bull Case for ABBV?
• Neutral Sentiment: General market write-ups and “best stock on a pullback” lists are circulating, which can attract retail interest but typically have limited immediate impact beyond amplifying existing momentum. AbbVie (ABBV): The Best Stock to Buy on a Pullback
• Negative Sentiment: Analyst caution ahead of next earnings: Zacks and some preview pieces note AbbVie may lack the setup for a clear earnings beat next quarter — a reminder that upcoming results and guidance could pressure the stock if they disappoint. AbbVie (ABBV) Earnings Expected to Grow: Should You Buy?

Analysts Set New Price Targets

A number of equities analysts have recently commented on ABBV shares. Barclays started coverage on shares of AbbVie in a report on Thursday, February 19th. They set an “overweight” rating and a $275.00 price target on the stock. William Blair restated an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a report on Wednesday, January 21st. BMO Capital Markets restated an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Finally, Wall Street Zen lowered shares of AbbVie from a “strong-buy” rating to a “buy” rating in a report on Saturday, April 11th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $253.43.

Insider Buying and Selling at AbbVie

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president directly owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. The trade was a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the sale, the senior vice president directly owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. This trade represents a 66.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.06% of the company’s stock.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.